JDRF and Arecor partnership to improve insulin

JDRF has announced a partnership with Arecor Ltd to support development of a stable, rapid-acting, ultra-concentrated insulin. Improved insulins would enable the miniaturization of next-generation insulin-delivery devices for people with Type 1 diabetes. The aim is to advance the pre-clinical trials of Arecor’s ultra-concentrated insulin. The ultimate goal of the partnership is to accelerate the development of a stable, rapid-acting, ultra-concentrated insulin of up to 1,000 U/mL, which will not only offer a vastly superior mealtime insulin product for people requiring less than 200 units a day, but is also a critical step towards the advancement of the miniaturization of delivery devices, including next-generation artificial pancreas systems for people with Type 1 diabetes.

This news item first appeared in Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.


Open publication

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags